211 related articles for article (PubMed ID: 31902734)
1. Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia.
Chen Y; Yin H; Chen L; Xiong Y; Meng L; Guo J; Wang H; Li W
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e43-e49. PubMed ID: 31902734
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of nilotinib
Yu L; Qin YZ; Lai YY; Shi HX; Huang XJ; Hou Y; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):996-1002. PubMed ID: 32023729
[No Abstract] [Full Text] [Related]
5. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
6. [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase].
Yin H; Chen LF; Cui JK; Xiong YY; You Y; Zou P; Li WM
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):810-815. PubMed ID: 29136709
[No Abstract] [Full Text] [Related]
7. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
8. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Cortes JE; De Souza CA; Ayala M; Lopez JL; Bullorsky E; Shah S; Huang X; Babu KG; Abdulkadyrov K; de Oliveira JSR; Shen ZX; Sacha T; Bendit I; Liang Z; Owugah T; Szczudlo T; Khanna S; Fellague-Chebra R; le Coutre PD
Lancet Haematol; 2016 Dec; 3(12):e581-e591. PubMed ID: 27890073
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Wang R; Cong Y; Li C; Zhang C; Lin H
Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
[TBL] [Abstract][Full Text] [Related]
10. Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib.
Yue Y; Gui X; He X; Chen Y; Pan J; Qiu H; Wu D; Chen S; Guo L; Cen J
Hematology; 2016 May; 21(4):213-7. PubMed ID: 26183593
[TBL] [Abstract][Full Text] [Related]
11. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
Wang YY; Zhao HG; Cui ZG; Li GL; Shi X; Xu H; Zhou Y; Zhao T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):356-63. PubMed ID: 25948185
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J; Matsumura I; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Matsuoka KI; Shibayama H; Hino M; Hirase C; Kamimura T; Shimose T; Akashi K; Kanakura Y
Int J Hematol; 2018 May; 107(5):535-540. PubMed ID: 29362980
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
17. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
19. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
[No Abstract] [Full Text] [Related]
20. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]